Salomon & Ludwin
ACAD icon

Salomon & Ludwin’s Acadia Pharmaceuticals ACAD Stock Holding History

Salomon & Ludwin’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$27.7K Hold
1,375
– – ﹤0.01% 757
2026
Q2 		$34.6K Sell
1,375
-551
-29% -$12.1K ﹤0.01% 754
2026
Q1 		$42.8K Buy
1,926
+1,009
+110% +$24.1K ﹤0.01% 561
2025
Q4 		$24K Buy
917
+401
+78% +$9.6K ﹤0.01% 762
2025
Q3 		$11.2K Buy
+516
New +$12.2K ﹤0.01% 1221

Other funds holding ACAD

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Salomon & Ludwin's ACAD Position: Q3 2026 in Review

Salomon & Ludwin held its Acadia Pharmaceuticals (ACAD) position steady in Q3 2026 at 1,375 shares worth $27.7K. The position accounts for ﹤0.01% of the portfolio, ranked #757.

Salomon & Ludwin first reported a position in ACAD in Q3 2025 and has held it in 5 quarters since. The position peaked at $42.8K in Q1 2026. 148 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Salomon & Ludwin held 1,375 shares of Acadia Pharmaceuticals worth $27.7K as of Q3 2026.
  • Salomon & Ludwin left its Acadia Pharmaceuticals share count unchanged in Q3 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q3 2026, its #757 holding.
  • Salomon & Ludwin first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Salomon & Ludwin's Acadia Pharmaceuticals position peaked at $42.8K in Q1 2026.
  • 148 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Salomon & Ludwin's 13F filing for Q3 2026, filed 29 Oct 2026.